Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) Stock
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
About Jiangxi Synergy Pharmaceutical Co., Ltd.
Jiangxi Synergy Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and fine chemicals in China and internationally. The company offers API products for anti-epilepsy and pain treatment, anti-inflammatory, gastrointestinal, anti-hypertension, anti-gout, anti-diabetes, anti-thrombotic, urology, non-alcoholic steatohepatitis, idiopathic parkinsonism, hypolipidemic agents, migraine therapy, prostate cancer, endometriosis, anemia, atopic dermatitis, nervous system, digestive system, antipyretic analgesics and non-steroidal anti-inflammatory, anticoagulant, hypoglycemic drug, and antidepressant indications. It also provides intermediate products, including rivaroxaban, apixaban, empagliflozin, canagliflozin, ipragliflozin, mirabegron, vibegron, agomelatine, febuxostat, vildagliptin, vonoprazan fumarate, dabigatran etexilate mesylate, azilsartan base and medoxomil potassium, candesartan cilexetil, rimegepant, resmetirom, and opicapone. In addition, the company offers contract manufacturing organization (CMO) services, including production capacity, good manufacturing practice (GMP), regulatory support, research and development for process optimization and scale-up production, and environmental, health, and safety (EHS) management systems. It exports its products to Europe, the United States, Japan, and South Korea. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) stock trades at $6.72 with a market capitalization of $2.82B. The stock is valued at a price-to-earnings (P/E) ratio of 74.67, price-to-book of 1.19, price-to-sales of 3.60. Over the past 52 weeks the stock has ranged between $6.11 and $8.93, and currently trades 24.7% below its 52-week high. It pays a dividend yielding 0.60%.
On profitability, Jiangxi Synergy Pharmaceutical Co., Ltd. generates a return on equity (ROE) of 1.66%, an operating margin of -0.03%, a net profit margin of 4.99%.
Official website: www.jxsynergy.com
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) — frequently asked questions
What is Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) stock price today?
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) is currently trading at $6.72, up 0.9% today.
What is 300636.SZ P/E ratio?
Jiangxi Synergy Pharmaceutical Co., Ltd.'s P/E ratio is 74.67. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.
What is 300636.SZ return on equity (ROE)?
Jiangxi Synergy Pharmaceutical Co., Ltd.'s return on equity (ROE) is 1.66%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.
What is Jiangxi Synergy Pharmaceutical Co., Ltd.'s market cap?
Jiangxi Synergy Pharmaceutical Co., Ltd. has a market capitalization of $2.82B.
Does 300636.SZ pay a dividend?
Yes. Jiangxi Synergy Pharmaceutical Co., Ltd. currently yields 0.60%. Yield moves with the share price, so it changes daily even when the payment does not.
How much debt does 300636.SZ carry?
Jiangxi Synergy Pharmaceutical Co., Ltd. has a debt-to-equity ratio of 0.19. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 300636.SZ's profit margin?
Jiangxi Synergy Pharmaceutical Co., Ltd. reports a net profit margin of 4.99% — the share of revenue left after every cost, including tax and interest.
What sector is 300636.SZ in?
Jiangxi Synergy Pharmaceutical Co., Ltd. is classified under Healthcare, in the Drug Manufacturers - Specialty & Generic industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 300636.SZ listed on?
Jiangxi Synergy Pharmaceutical Co., Ltd. trades on SHZ under the ticker 300636.SZ.
What is 300636.SZ's 52-week range?
Over the last year Jiangxi Synergy Pharmaceutical Co., Ltd. has traded between $6.11 and $8.93.
Related Healthcare Stocks
Popular Stocks
Screens 300636.SZ currently matches
On the figures above, Jiangxi Synergy Pharmaceutical Co., Ltd. passes the filters for 7 of our ready-made screens, among them Low Debt Stocks, Stocks Under $10, High PE Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.